Analyst consensus rating
Ascendis Pharma Analyst Rating: Strong Buy
Direct answer
Ascendis Pharma's consensus rating is Strong Buy.
21 analysts are included in the current consensus when a coverage count is available.
The same consensus reports an average price target of $304.85.
Forecast evidence checked November 10, 2026.
Get free Ascendis Pharma email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Current price
- $255.75
- Average price target
- $304.85
- High price target
- $342.43
- Low price target
- $261.17
- Low target gap
- +2.1%
- Target upside
- +19.2%
- High target gap
- +33.9%
- Target range width
- 31.8%
- Consensus rating
- Strong Buy
- Analysts
- 21
- Evidence date
- November 10, 2026
- Valid through
- November 17, 2026
Explore related company data
Read the frequently asked questions.
What is the analyst consensus rating for Ascendis Pharma?
Ascendis Pharma has a verified Strong Buy consensus. The same dataset has an average price target of $304.85.
How far are Ascendis Pharma's low and high targets from the recorded price?
The low target implies +2.1%, while the high target implies +33.9%.
How many analysts are included in Ascendis Pharma's consensus?
The verified consensus includes 21 analysts.
How is Ascendis Pharma's target upside or downside calculated?
The average target of $304.85 is divided by the recorded price of $255.75, then one is subtracted to produce +19.2%. This does not guarantee a future return.
When was Ascendis Pharma's analyst forecast verified?
The data was verified on 2026-11-10. The dataset is valid through 2026-11-17.